Cross-resistance to nitro drugs and implications for treatment of human african trypanosomiasis

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 7, 2010, Pages 2893-2900

  Sokolova, Antoaneta Y ^a   Wyllie, Susan ^a   Patterson, Stephen ^a   Oza, Sandra L ^a   Read, Kevin D ^a   Fairlamb, Alan H ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; FEXINIDAZOLE; NIFURTIMOX; ANTITRYPANOSOMAL AGENT; EFLORNITHINE;

AFRICAN TRYPANOSOMIASIS; ANTIMALARIAL DRUG RESISTANCE; ANTIMALARIAL DRUG SUSCEPTIBILITY; ARTICLE; CELL LINE; CROSS RESISTANCE; DRUG EXPOSURE; DRUG METABOLISM; GENE; MOUSE; NFXR1 GENE; NFXR2 GENE; NONHUMAN; PARASITE VIRULENCE; PRIORITY JOURNAL; TRYPANOSOMA BRUCEI; ANIMAL; DRUG EFFECTS; DRUG RESISTANCE; HUMAN; METABOLISM; PARASITOLOGY; PATHOGENICITY; TRYPANOSOMA BRUCEI BRUCEI; TRYPANOSOMIASIS, AFRICAN;

ANIMALS; CELL LINE; DRUG RESISTANCE; EFLORNITHINE; HUMANS; MICE; NIFURTIMOX; TRYPANOCIDAL AGENTS; TRYPANOSOMA BRUCEI BRUCEI; TRYPANOSOMIASIS, AFRICAN;

EID: 77953760001     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00332-10     Document Type: Article

References (42)

1. Apted, F. I. C. 1980. Present status of chemotherapy and chemoprophylaxis of human trypanosomiasis in the eastern hemisphere. Pharmacol. Ther. 11:391-413.
2. Barrett, M. P., and A. H. Fairlamb. 1999. The biochemical basis of arsenical-diamidine cross-resistance in African trypanosomes. Parasitol. Today 15:136-140.
3. Barry, C. E., H. I. M. Boshoff, and C. S. Dowd. 2004. Prospects for clinical introduction of nitroimidazole antibiotics for the treatment of tuberculosis. Curr. Pharm. Des. 10:3239-3262.
4. Bisser, S., F. X. N'Siesi, V. Lejon, P. M. Preux, S. Van Nieuwenhove, C. M. M. Bilenge, and P. Buscher. 2007. Equivalence trial of melarsoprol and nifurtimox monotherapy and combination therapy for the treatment of second-stage Trypanosoma brucei gambiense sleeping sickness. J. Infect. Dis. 195:322-329.
5. Bouteille, B., O. Oukem, S. Bisser, and M. Dumas. 2003. Treatment perspectives for human African trypanosomiasis. Fundam. Clin. Pharmacol. 17:171-181.
6. Bryant, D. W., D. R. McCalla, M. Leeksma, and P. Laneuville. 1981. Type I nitroreductases of Escherichia coli. Can. J. Microbiol. 27:81-86.
7. Chauviere, G., B. Bouteille, B. Enanga, C. de Albuquerque, S. L. Croft, M. Dumas, and J. Perie. 2003. Synthesis and biological activity of nitro heterocycles analogous to megazol, a trypanocidal lead. J. Med. Chem. 46:427-440.
8. DNDi. 2009. Annual report 2008-2009. Delivering innovation and building a robust pipeline. Drugs for Neglected Diseases Initiative, Geneva, Switzerland.
9. Docampo, R., and S. N. J. Moreno. 1984. Free radical metabolites in the mode of action of chemotherapeutic agents and phagocytic cells on Trypanosoma cruzi. Rev. Infect. Dis. 6:223-238.
10. Docampo, R., and S. N. J. Moreno. 1986. Free-radical metabolism of antiparasitic agents. Fed. Proc. 45:2471-2476.
11. Dunne, R. L., L. A. Dunn, P. Upcroft, P. J. O'Donoghue, and J. A. Upcroft. 2003. Drug resistance in the sexually transmitted protozoan Trichomonas vaginalis. Cell Res. 13:239-249.
12. Fairlamb, A. H. 2003. Chemotherapy of human African trypanosomiasis: current and future prospects. Trends Parasitol. 19:488-494.
13. Fairlamb, A. H., N. S. Carter, M. Cunningham, and K. Smith. 1992. Characterisation of melarsen-resistant Trypanosoma brucei brucei with respect to cross-resistance to other drugs and trypanothione metabolism. Mol. Biochem. Parasitol. 53:213-222.
14. Fairlamb, A. H., G. B. Henderson, C. J. Bacchi, and A. Cerami. 1987. In vivo effects of difluoromethylornithine on trypanothione and polyamine levels in bloodstream forms of Trypanosoma brucei. Mol. Biochem. Parasitol. 24:185-191.
15. Ginsberg, A. M., M. W. Laurenzi, D. J. Rouse, K. D. Whitney, and M. K. Spigelman. 2009. Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects. Antimicrob. Agents Chemother. 53:3720-3725.
16. Greig, N., S. Wyllie, S. Patterson, and A. H. Fairlamb. 2009. A comparative study of methylglyoxal metabolism in trypanosomatids. FEBS J. 276:376-386.
17. Hirumi, H., and K. Hirumi. 1989. Continuous cultivation of Trypanosoma brucei blood stream forms in a medium containing a low concentration of serum protein without feeder cell layers. J. Parasitol. 75:985-989. (Pubitemid 20099178)
18. Hoff, D. R., and D. W. Henry. January 1967. Nitroimidazoles. U.S. patent 3,299,090.
19. Imlay, J. A. 2003. Pathways of oxidative damage. Annu. Rev. Microbiol. 57:395-418.
20. Jennings, F. W., and G. M. Urquhart. 1983. The use of the 2 substituted 5-nitroimidazole, fexinidazole (Hoe 239) in the treatment of chronic T. brucei infections in mice. Z. Parasitenkd. 69:577-581.
21. Jones, D. C., A. Ariza, W. H. Chow, S. L. Oza, and A. H. Fairlamb. 2010. Comparative structural, kinetic and inhibitor studies of Trypanosoma brucei trypanothione reductase with T. cruzi. Mol. Biochem. Parasitol. 169:12-19.
22. Knox, R. J., P. J. Burke, S. Chen, and D. J. Kerr. 2003. CB 1954: from the Walker tumor to NQO2 and VDEPT. Curr. Pharm. Des. 9:2091-2104.
23. Legros, D., G. Ollivier, M. Gastellu-Etchegorry, C. Paquet, C. Burri, J. Jannin, and P. Buscher. 2002. Treatment of human African trypanosomiasis - present situation and needs for research and development. Lancet Infect. Dis. 2:437-440.
24. Leitsch, D., D. Kolarich, M. Binder, J. Stadlmann, F. Altmann, and M. Duchêne. 2009. Trichomonas vaginalis: metronidazole and other nitroimidazole drugs are reduced by the flavin enzyme thioredoxin reductase and disrupt the cellular redox system. Implications for nitroimidazole toxicity and resistance. Mol. Microbiol. 72:518-536.
25. Likeufack, A. C. L., R. Brun, A. Fomena, and P. Truc. 2006. Comparison of the in vitro drug sensitivity of Trypanosoma brucei gambiense strains from West and Central Africa isolated in the periods 1960-1995 and 1999-2004. Acta Trop. 100:11-16.
26. Maina, N., K. J. Maina, P. Maser, and R. Brun. 2007. Genotypic and phenotypic characterization of Trypanosoma brucei gambiense isolates from Ibba, South Sudan, an area of high melarsoprol treatment failure rate. Acta Trop. 104:84-90.
27. Manjunatha, U., H. I. Boshoff, and C. E. Barry. 2009. The mechanism of action of PA-824: novel insights from transcriptional profiling. Commun. Integr. Biol. 2:215-218.
28. Murta, S. M., R. T. Gazzinelli, Z. Brener, and A. J. Romanha. 1998. Molecular characterization of susceptible and naturally resistant strains of Trypanosoma cruzi to benznidazole and nifurtimox. Mol. Biochem. Parasitol. 93:203-214.
29. Nuermberger, E., S. Tyagi, R. Tasneen, K. N. Williams, D. Almeida, I. Rosenthal, and J. H. Grosset. 2008. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis. Antimicrob. Agents Chemother. 52:1522-1524.
30. Orita, A., K. Miwa, G. Uehara, and J. Otera. 2007. Integration of solventless reaction in a multi-step process: application to an efficient synthesis of PA-824. Adv. Synth. Catal. 349:2136-2144.
31. Paulos, C., J. Paredes, I. Vasquez, S. Thambo, A. Arancibia, and G. Gonzalez-Martin. 1989. Pharmacokinetics of a nitrofuran compound, nifurtimox, in healthy volunteers. Int. J. Clin. Pharmacol. 27:454-457.
32. Priotto, G., S. Kasparian, W. Mutombo, D. Ngouama, S. Ghorashian, U. Arnold, S. Ghabri, E. Baudin, V. Buard, S. Kazadi-Kyanza, M. Ilunga, W. Mutangala, G. Pohlig, C. Schmid, U. Karunakara, E. Torreele, and V. Kande. 2009. Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial. Lancet 374:56-64.
33. Race, P. R., A. L. Lovering, R. M. Green, A. Ossor, S. A. White, P. F. Searle, C. J. Wrighton, and E. I. Hyde. 2005. Structural and mechanistic studies of Escherichia coli nitroreductase with the antibiotic nitrofurazone. Reversed binding orientations in different redox states of the enzyme. J. Biol. Chem. 280:13256-13264.
34. Sienkiewicz, N., S. Jaroslawski, S. Wyllie, and A. H. Fairlamb. 2008. Chemical and genetic validation of dihydrofolate reductase-thymidylate synthase as a drug target in African trypanosomes. Mol. Microbiol. 69:520-533.
35. Singh, R., U. Manjunatha, H. I. M. Boshoff, Y. H. Ha, P. Niyomrattanakit, R. Ledwidge, C. S. Dowd, I. Y. Lee, P. Kim, L. Zhang, S. H. Kang, T. H. Keller, J. Jiricek, and C. E. I. Barry. 2008. PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science 322:1392-1395.
36. Stuart, K. D., R. Brun, S. L. Croft, A. H. Fairlamb, R. E. Gurtler, J. H. McKerrow, S. Reed, and R. L. Tarleton. 2008. Kinetoplastids: related protozoan pathogens, different diseases. J. Clin. Invest. 118:1301-1310.
37. Swamy, K. C. K., N. N. B. Kumar, E. Balaraman, and K. V. P. P. Kumar. 2009. Mitsunobu and related reactions: advances and applications. Chem. Rev. 109:2551-2651.
38. White, N. J., and P. L. Olliaro. 1996. Strategies for the prevention of antimalarial drug resistance: rationale for combination chemotherapy for malaria. Parasitol. Today 12:399-401.
39. Wilkinson, S. R., M. C. Taylor, D. Horn, J. M. Kelly, and I. Cheeseman. 2008. A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes. Proc. Natl. Acad. Sci. U. S. A. 105:5022-5027.
40. Winkelmann, E., and W. Raether. August 1977. 1-Methyl-2-(phenyl- oxymethyl)-5-nitro-imidazoles and process for their manufacture. U.S. patent 4,042,705.
41. Winkelmann, E., and W. Raether. 1978. Chemotherapeutically active nitro compounds. 4. 5-Nitroimidazoles (part III). Arzneimittelforschung 28:739-749.
42. World Health Organization. 2004. The world health report 2004: changing history. World Health Organization, Geneva, Switzerland.